Biomedical startup GeronMed announced on the 11th that it was finally selected for the '2025 Industry-Academia-Research Collabo R&D (General Type)' project hosted by the Ministry of SMEs and Startups, together with the research team of Professor Yoo Im-ju of Korea University College of Medicine.
The purpose of this project is to verify the clinical efficacy and safety of soropsin recombinant protein for diagnosing degenerative brain diseases and to establish a foundation for commercialization of the technology. GeronMed and Korea University College of Medicine plan to launch a full-scale verification study for the development of in vitro diagnostic medical devices through joint research.
The soropsen recombinant protein used in the study is a core technology with high potential for commercialization as a raw material for biopharmaceuticals and diagnostic reagents, and its potential for use in the field of degenerative brain diseases will be evaluated after scientific verification through animal models. This project is attracting attention as a joint research and development case that seeks the possibility of commercializing diagnostic and therapeutic technologies beyond understanding the pathogenesis.
The research team of Professor Yoo Im-ju of Korea University College of Medicine is a specialized group with numerous research achievements in the fields of brain science and brain histology. Through this collaboration, they plan to strengthen the joint research system between academia, industry, and research and advance the diagnostic and treatment-based technologies for degenerative brain diseases.
Meanwhile, the company said it has strengthened its commercialization foundation by obtaining an in vitro diagnostic medical device manufacturing license in the second half of 2024, and plans to lay the foundation for entering the global diagnostic reagent market through this government project.
- See more related articles
You must be logged in to post a comment.